TOPIC 319 PHASE I; TECHNOLOGY TO GENERATE ANTI PEPTICE CAPTURE REAGENS AFFINITY E
TOPIC 319 PHASE I; TECHNOLOGY TO GENERATE ANTI PEPTICE CAPTURE REAGENS AFFINITY E
批准号:
8762565
负责人:
MARK MORRIS
金额:
$19.96万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-13 至 2014-06-12
关键词:
AffinityBiological AssayCommunitiesContractsDevelopmentEvaluationImmunoprecipitationLigandsMalignant NeoplasmsMeasurementPeptidesPerformancePhasePrivate SectorProductionPublic SectorReagentRunningSmall Business Innovation Research GrantSpecificityTechnologyTestingValidationWorkaptamercost effectivenessimprovednovel
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The stated Phase I activities and expected deliverables of this SBIR Contract include: 1) Development of
proof-of-concept technologies that reliably generate anti-peptide capture reagents that can
immunoprecipitate the target peptides; 2) Demonstrate that the capture reagents developed can reproducibly
immunoprecipitate the target peptides; 3) Work with the CPTC community, private and public sector to
identify minimum characterization criteria for validation of the assays; 4) Generate affinity reagents to at least
ten proteotypic peptides and demonstrate high affinity, specificity and immunoprecipitation performance; 5)
Make available to NCI sufficient reagents to perform 10 test runs for each of the ten peptides for independent
evaluation; 6) Present findings to an NCI CPTC Evaluation Panel demonstrating how the capture reagents
have improved cost effectiveness and throughput capabilities in production.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金